If type and crossmatch is obtained before initiating treatment with daratumumab, what good would that do if a transfusion is required a month later?
Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.
BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.
Genome editing technology illustrates progression of normal blood cells to leukemia.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.
Ambulatory bloodstream infections in pediatric oncology and stem cell transplant patients result in significant health care charges and extended hospital admissions.
Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Bone marrow transplantation can be improved by optimizing the dose of transplanted hematopoietic stem cells, according to recent results from a mouse model.
Incidence of frailty among young survivors of bone marrow transplant is similar to that of the elderly population, and increases the risk of death compared with nonfrail survivors.
High-risk medications can increase falls in patients undergoing treatment for malignant hematology, but implementing risk-specific fall prevention strategies can ameliorate the effects of the drugs.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?
A calculator for determining Expected PCO2 (Winters).
Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood CancersJanuary 04, 2016
In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.
High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With AmyloidosisOctober 27, 2015
Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.
Implementing proactive telephone support reduced unplanned hospitalizations among patients with blood cancers by 70%.
DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be effective in a small group of patients with relapsed/refractory B-cell malignancies, according to clinical trial results.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
The risk of developing therapy-related acute myeloid leukemia after chemotherapy varies depending on initial cancer and treatment practices.
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
A round-up of some of the top developments in hematology and oncology in December 2012.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- A Witness to Letting Go: Nursing Care at the End of Life
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|